Stockholders' Equity | 8. Stockholders’ Equity Stock Compensation Performance Shares (Restricted Stock Awards) During the nine months ended March 31, 2018, the Company granted 57,416 restricted stock awards that carry both performance and service conditions to vest with an estimated grant date fair value of approximately $0.2 million. As of March 31, 2018, the Company had 761,617 restricted stock awards that carry both performance and service conditions to vest. The awards vest over a five-year service period, with the first twenty percent of the award vesting on the first anniversary of the grant, and the remaining award vesting quarterly through November 3, 2021. In addition, the restricted stock awards are subject to pro-rated forfeiture based on the collection of cumulative fees under the GECC investment management agreement of at least $40 million for the five-year period ended November 3, 2021. The Company estimates the performance condition is probable of being achieved. The Company accounts for forfeitures of the restricted stock awards in the period incurred. During the nine months ended March 31, 2018, 256,808 restricted stock awards were forfeited. All previously recognized compensation cost associated with the forfeiture during the period, totaling $0.5 million, was reversed. Additionally, in September 2017, the Company modified all of the outstanding restricted stock awards to include a change in control acceleration event. This modification did not result in the recognition of an additional compensation cost. For the three and nine months ended March 31, 2018, the Company recognized compensation cost totaling $0.4 million and $0.8 million, respectively, associated with the performance-based awards. For the three and nine-month periods ended March 31, 2017, the Company recognized compensation cost totaling $0.5 million and $0.8 million, respectively. The following table summarizes the Company’s restricted stock award activity as of and through March 31, 2018 (in thousands, except per share amounts): Weighted Average Restricted Grant Date Restricted Stock Awards and Units Stock Fair Value Outstanding at June 30, 2017 1,147 $ 3.88 Granted 75 3.57 Vested (185 ) 3.55 Forfeited (257 ) 3.95 Outstanding at March 31, 2018 780 $ 3.91 Stock Options During the nine months ended March 31, 2018, the Company issued 2,082,736 stock options with an estimated grant date fair value of $4.1 million. The Company utilizes a Black-Scholes option pricing model to estimate the fair value of its option awards. The assumptions used to value the stock options granted during the nine-months ended March 31, 2018 consisted of: expected volatilities between 60.8 to 63.4%; no expected dividend yields; risk-free rates between 1.5 and 2.5%; and expected terms between 3 and 6.5 years. The following table summarizes the Company’s option award activity as of and through March 31, 2018 (in thousands, except per share amounts): Weighted Average Weighted Remaining Average Contractual Aggregate Options Options Exercise Price Term (years) Intrinsic Value Outstanding at June 30, 2017 722 $ 7.46 Options granted 2,083 3.60 Exercised — — Forfeited, cancelled or expired (128 ) 10.45 Outstanding at March 31, 2018 2,677 $ 4.31 7.69 $ 958 Exercisable at March 31, 2018 864 5.83 6.30 213 Vested and expected to vest as of March 31, 2018 2,677 $ 4.31 7.69 $ 958 During the three months and nine months ended March 31, 2018, the Company recognized total stock-based compensation associated with all restricted stock and stock options of $0.9 million and $3.6 million, respectively. During the three months and nine months ended March 31, 2017, the Company recognized total stock based compensation associated with all restricted stock and stock options of $0.6 million and $1.3 million, respectively. As of March 31, 2018, unrecognized compensation costs associated with outstanding stock and stock-linked awards totaled approximately $4.5 million. GP Corp. Stock - Non-Controlling Interest In September 2017, the Company eliminated the vesting provisions and removed the call rights for the GP Corp. stock owned by employees of the Company. As a result of the elimination, the Company recognized stock-based compensation expense of $1.5 million for the nine months ended March 31, 2018, equal to the estimated fair value of the non-controlling interest held by our employees in GP Corp. Other Equity Transactions Warrants During the nine months ended March 31, 2018, the Company issued warrants to purchase 1,686,000 shares of common stock with an estimated grant date fair value of $0.05 million. The exercise price of the warrants is variable and based on the average of quoted market prices for the ten days preceding notice of exercise. The Company utilized a Monte-Carlo simulation model to estimate the fair value of its equity-classified warrant issuances. The following table illustrates the Company’s warrant activity as of and through March 31, 2018 (in thousands, except per share amounts): Weighted Average Weighted Remaining Average Contractual Aggregate Warrants Shares Exercise Price Term (years) Intrinsic Value Outstanding at June 30, 2017 55 $ 0.01 Granted 1,686 3.60 Exercised (1,266 ) 3.60 Forfeited, cancelled or expired (55 ) 0.01 Outstanding at March 31, 2018 420 $ 4.00 1.47 $ — Exercisable and vested at March 31, 2018 420 $ 4.00 1.47 $ — During the nine months ended March 31, 2018, the Company received cash proceeds totaling $4.6 million from the exercise of 1,266,000 warrants by a designee of Northern Right Capital. Matthew A. Drapkin, a member of the Company’s board of directors, is the Chief Executive Officer of Northern Right Capital. The Company had classified the MAST Warrant as a liability and valued, on a recurring basis, using a Black-Scholes-Merton option pricing model and Level 3 inputs within the fair value hierarchy. In September 2017, the Company exchanged the MAST Warrant for 54,733 shares of common stock. The following table sets forth a summary of the changes in the fair value of the Company’s warrant liability that was measured at fair value on a recurring basis (in thousands): March 31, 2018 June 30, 2017 Beginning of period $ 186 $ — Aggregate fair value of warrant issued — 216 Re-measurement of warrant liability loss (gain) 8 (30 ) Settlement (194 ) — End of period $ — $ 186 |